Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000.

نویسندگان

  • Diane K Wysowski
  • Joslyn Swann
  • Amarilys Vega
چکیده

BACKGROUND Isotretinoin, a drug approved to treat severe recalcitrant nodular acne, has been marketed in the United States since 1982. The drug is an effective treatment for acne that is refractory to other therapies, but it is a teratogen and can cause serious side effects. OBJECTIVE Our purpose was to describe trends in the use of isotretinoin in the United States from marketing through year 2000 and summarize characteristics of patients and prescribers. METHODS Data from 2 pharmaceutical marketing research databases, the National Prescription Audit Plus and the National Disease and Therapeutic Index, and from 2 health plan networks were obtained and analyzed. RESULTS Retail pharmacies dispensed 19.8 million outpatient prescriptions for isotretinoin from marketing in 1982 through 2000. From 1983 through 1993, the median annual number of prescriptions was just over 800,000; between 1992 and 2000, the number of prescriptions increased 2.5-fold (250%) to nearly 2 million in year 2000. The increases registered in the health plans were somewhat larger: about 275% increases from 1995 through 1999. There is no ICD-9 code for nodulocystic acne; consequently, the type of acne treated with isotretinoin is not determinable from these data. However, between 1993 and 2000, the proportion of isotretinoin treatment for severe acne declined from 63% to 46%, whereas the proportion of treatment for mild and moderate acne increased from 31% to 49%. Data also indicated that the sex distribution of patients was nearly even, and that 63% of male patients prescribed isotretinoin were 15 to 19 years old, whereas 51% of female patients were 15 to 24 years old. CONCLUSION In the last 8 years, there has been a 2.5-fold (250%) increase in the number of dispensed prescriptions for isotretinoin in the United States. Data also reveal an increasing proportion of isotretinoin use for mild and moderate acne.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Executive Summary: Clinical

Accutane “NF” is a new formulation of isotretinoin, a drug substance that was approved in 1982. The indication remains severe recalcitrant nodular acne. The Sponsor’s stated reason for pursuing this new formulation is that improved bioavailability will allow once daily dosing with or without food, as opposed to twice daily with food as per labeling for the current Accutane® formulation. The Spo...

متن کامل

Accutane® (isotretinoin) Capsules 1. BENEFITS OF ACCUTANE 1.1 Etiology and Pathology of Acne

Acne is the most common disease treated by dermatologists based upon data from the 1996 U.S. Census. The lifetime prevalence of acne approaches 90%. Acne vulgaris is a chronic disease with the highest prevalence in adolescents. The onset of acne vulgaris occurs during the onset of puberty, which is at a younger chronological age in females than in males. Both females and males have acne that ex...

متن کامل

Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration.

Recessive Stargardt's macular degeneration is an inherited blinding disease of children caused by mutations in the ABCR gene. The primary pathologic defect in Stargardt's disease is accumulation of toxic lipofuscin pigments such as N-retinylidene-N-retinylethanolamine (A2E) in cells of the retinal pigment epithelium. This accumulation appears to be responsible for the photoreceptor death and se...

متن کامل

The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).

The Food and Drug Administration (“FDA” “Agency”) continues to face one of the most intractable issues of its tenure: deciding whether and when efficacious treatments that may harm fetuses should be available on the market. Currently, the Agency weighs the benefits of such medication with the risk of fetal malformation, factoring the expected reduction of risk accomplished with the utilization ...

متن کامل

Isotretinoin (Accutane) as a Teratogen

Isotretinoin is a molecule and a byproduct (metabolite) of vitamin A, and in greater than normal amounts in pregnant women, it can cause fetal abnormalities including cleft lips, ear and eye defects, and mental retardation [5]. Isotretinoin is commonly called by its trade name Accutane, and it's a chemical compound derived from vitamin A, also called retinoic acid. Doctors prescribe isotretinoi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of the American Academy of Dermatology

دوره 46 4  شماره 

صفحات  -

تاریخ انتشار 2002